Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1986 1
1987 2
1988 1
1989 1
1991 1
1992 3
1993 1
1994 2
1995 2
1997 1
1998 1
2000 2
2001 1
2002 4
2004 1
2006 1
2008 3
2009 1
2010 1
2011 3
2012 5
2013 2
2014 6
2015 6
2016 7
2017 6
2018 5
2019 10
2020 8
2022 2
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. González-Martín A, et al. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Konstantinopoulos PA, et al. Among authors: colon otero g. JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. JAMA Oncol. 2019. PMID: 31194228 Free PMC article.
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Perez EA, et al. Among authors: colon otero g. J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332249 Free PMC article. Clinical Trial.
Dual HER2 blockade: preclinical and clinical data.
Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Patel TA, et al. Among authors: colon otero g. Breast Cancer Res. 2014 Aug 1;16(4):419. doi: 10.1186/s13058-014-0419-5. Breast Cancer Res. 2014. PMID: 25928889 Free PMC article. Review.
Mayo Clinic Alix School of Medicine.
Reed DA, Harrison ME, Wolanskyj-Spinner AP, Dixon DA, Halyard MY, Colon-Otero G, Andresen-Reid ML, Meyer FB. Reed DA, et al. Among authors: colon otero g. Acad Med. 2020 Sep;95(9S A Snapshot of Medical Student Education in the United States and Canada: Reports From 145 Schools):S262-S265. doi: 10.1097/ACM.0000000000003454. Acad Med. 2020. PMID: 33626696 No abstract available.
How to diagnose bleeding disorders.
Colon-Otero G, Cockerill KJ, Bowie EJ. Colon-Otero G, et al. Postgrad Med. 1991 Sep 1;90(3):145-50. doi: 10.1080/00325481.1991.11701040. Postgrad Med. 1991. PMID: 1881848 Review.
Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.
Chumsri S, Pai T, Ma Y, Li Z, Gil A, Moreno-Aspitia A, Colon-Otero G, Pogue-Geile KL, Rasgoti P, Paik S, Perez EA, Thompson EA. Chumsri S, et al. Among authors: colon otero g. J Natl Compr Canc Netw. 2024 Aug 26;22(7):463-468. doi: 10.6004/jnccn.2024.7015. J Natl Compr Canc Netw. 2024. PMID: 39191270 Free PMC article. Clinical Trial.
The Biology of Breast Cancer Disparities in Hispanics: Current Knowledge, Gaps, and Research Opportunities.
Colon-Otero G. Colon-Otero G. 2019 Dec 13. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos [Internet]. Cham (CH): Springer; 2020. Chapter 9. 2019 Dec 13. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos [Internet]. Cham (CH): Springer; 2020. Chapter 9. PMID: 34460191 Free Books & Documents. Review.
90 results